{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:40:57Z","timestamp":1781188857147,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsches Herzzentrum M\u00fcnchen"},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"advanceCOR GmbH"},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with coronary artery disease (CAD) are at increased risk of developing ischemic events and contemporary antiplatelet therapy often leads to bleeding events following percutaneous coronary intervention (PCI). Glycoprotein VI (GPVI) is the key receptor of collagen-dependent thrombus formation and crucial for platelet homeostasis.  <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analysed the influence of GPVI inhibition with revacept in a randomized double-blinded trial enrolling 334 patients with CAD undergoing elective PCI. Ex vivo platelet function analyses were assessed alongside plasma chemokine concentrations. We then elucidate changes of GPVI-dependent chemokine concentrations in patients with bleeding events during the 30-day clinical follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Changes in platelet function occur in patients with revacept treatment and are associated with a characteristic alteration of circulating chemokine concentrations. Further, patients with adverse bleeding events share a distinct fingerprint of chemokines that is associated with modulation of in vitro platelet functions. In addition, assessment of GPVI-associated changes in chemokine signalling and platelet functions demonstrated an increased diagnostic value in patients with CAD and might improve early risk discrimination for bleeding events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The composition of platelet-derived chemokines correlated with platelet functions following antiplatelet treatment. Thus, assessment of chemokines may offer the perspective to identify patients at increased risk for bleeding events. Likewise, modulation of platelet chemokines in patients with revacept treatment contributes to the efficacy of antiplatelet treatment and might attenuate pathophysiological cascades leading to haemorrhagic diathesis in patients with CAD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n            <jats:p>Study design and rationale: patients with coronary artery disease (CAD) undergoing elective percutaneous coronary intervention (PCI) and the impact of treatment with soluble GPVI inhibitor revacept. Changes in ex vivo platelet function and plasma chemokine concentrations were associated with an increased bleeding risk during the clinical follow-up. Further, GPVI-associated changes in chemokine signalling might attenuate pathophysiological cascades leading to haemorrhagic diathesis and improve early risk discrimination for bleeding events<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00392-025-02675-8","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:42:31Z","timestamp":1747806151000},"page":"1071-1083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Plasma chemokines indicate enhanced bleeding in patients with chronic coronary syndrome undergoing percutaneous coronary stenting"],"prefix":"10.1007","volume":"114","author":[{"given":"Tobias","family":"Harm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shqipdona","family":"Lahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Anne Lydia","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Janisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6tz","family":"M\u00fcnch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1124-9592","authenticated-orcid":false,"given":"Meinrad Paul","family":"Gawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"12","key":"2675_CR1","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1172\/jci27196","volume":"115","author":"M Gawaz","year":"2005","unstructured":"Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115(12):3378\u20133384. https:\/\/doi.org\/10.1172\/jci27196","journal-title":"J Clin Invest"},{"issue":"4","key":"2675_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1160\/th15-09-0742","volume":"115","author":"JL Reny","year":"2016","unstructured":"Reny JL, Fontana P, Hochholzer W, Neumann FJ, Ten Berg J, Janssen PW, Geisler T, Gawaz M, Marcucci R, Gori AM, Cuisset T, Alessi MC, Berdague P, Gurbel PA, Yong G, Angiolillo DJ, Aradi D, Beigel R, Campo G, Combescure C (2016) Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. Thromb Haemost 115(4):844\u2013855. https:\/\/doi.org\/10.1160\/th15-09-0742","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"2675_CR3","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/s0049-3848(10)70151-1","volume":"127","author":"BP Nuyttens","year":"2011","unstructured":"Nuyttens BP, Thijs T, Deckmyn H, Broos K (2011) Platelet adhesion to collagen. Thromb Res 127(Suppl 2):S26-29. https:\/\/doi.org\/10.1016\/s0049-3848(10)70151-1","journal-title":"Thromb Res"},{"issue":"11","key":"2675_CR4","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1161\/ATVBAHA.121.316108","volume":"41","author":"G Perrella","year":"2021","unstructured":"Perrella G, Nagy M, Watson SP, Heemskerk JWM (2021) Platelet GPVI (glycoprotein VI) and thrombotic complications in the venous system. Arterioscler Thromb Vasc Biol 41(11):2681\u20132692. https:\/\/doi.org\/10.1161\/ATVBAHA.121.316108","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2675_CR5","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2019.01731","volume":"10","author":"M Mezger","year":"2019","unstructured":"Mezger M, Nording H, Sauter R, Graf T, Heim C, von Bubnoff N, Ensminger SM, Langer HF (2019) Platelets and immune responses during thromboinflammation. Front Immunol 10:1731. https:\/\/doi.org\/10.3389\/fimmu.2019.01731","journal-title":"Front Immunol"},{"key":"2675_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa080","author":"A Witte","year":"2020","unstructured":"Witte A, Rohlfing AK, Dannenmann B, Dicenta V, Nasri M, Kolb K, Sudmann J, Castor T, Rath D, Borst O, Skokowa J, Gawaz M (2020) The chemokine CXCL14 mediates platelet function and migration via direct interaction with CXCR4. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvaa080","journal-title":"Cardiovasc Res"},{"issue":"11","key":"2675_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1161\/circresaha.115.305171","volume":"115","author":"M Chatterjee","year":"2014","unstructured":"Chatterjee M, Borst O, Walker B, Fotinos A, Vogel S, Seizer P, Mack A, Alampour-Rajabi S, Rath D, Geisler T, Lang F, Langer HF, Bernhagen J, Gawaz M (2014) Macrophage migration inhibitory factor limits activation-induced apoptosis of platelets via CXCR7-dependent Akt signaling. Circ Res 115(11):939\u2013949. https:\/\/doi.org\/10.1161\/circresaha.115.305171","journal-title":"Circ Res"},{"issue":"6","key":"2675_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1161\/01.RES.0000160077.17427.57","volume":"96","author":"C Weber","year":"2005","unstructured":"Weber C (2005) Platelets and chemokines in atherosclerosis. Circ Res 96(6):612\u2013616. https:\/\/doi.org\/10.1161\/01.RES.0000160077.17427.57","journal-title":"Circ Res"},{"issue":"1","key":"2675_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ahj.2008.02.010","volume":"156","author":"B Bigalke","year":"2008","unstructured":"Bigalke B, Geisler T, Stellos K, Langer H, Daub K, Kremmer E, Seizer P, May AE, Lindemann S, Gawaz M (2008) Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J 156(1):193\u2013200. https:\/\/doi.org\/10.1016\/j.ahj.2008.02.010","journal-title":"Am Heart J"},{"issue":"5","key":"2675_CR10","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1016\/j.thromres.2010.01.005","volume":"125","author":"B Bigalke","year":"2010","unstructured":"Bigalke B, Haap M, Stellos K, Geisler T, Seizer P, Kremmer E, Overkamp D, Gawaz M (2010) Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thromb Res 125(5):e184-189. https:\/\/doi.org\/10.1016\/j.thromres.2010.01.005","journal-title":"Thromb Res"},{"issue":"04","key":"2675_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00392-009-0109-y","volume":"99","author":"B Bigalke","year":"2010","unstructured":"Bigalke B, Stellos K, Geisler T, Lindemann S, May AE, Gawaz M (2010) Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clin Res Cardiol 99(04):227\u2013233. https:\/\/doi.org\/10.1007\/s00392-009-0109-y","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"2675_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood-2002-12-3882","volume":"102","author":"B Nieswandt","year":"2003","unstructured":"Nieswandt B, Watson SP (2003) Platelet-collagen interaction: is GPVI the central receptor? Blood 102(2):449\u2013461. https:\/\/doi.org\/10.1182\/blood-2002-12-3882","journal-title":"Blood"},{"key":"2675_CR13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1772221","author":"S Lahu","year":"2023","unstructured":"Lahu S, Adler K, Mayer K, Hein-Rothweiler R, Bernlochner I, Ndrepepa G, Sch\u00fcpke S, Holdenrieder S, Bongiovanni D, Laugwitz KL, Schunkert H, Gawaz M, Massberg S, Kastrati A, M\u00fcnch G (2023) Plasma soluble glycoprotein VI, platelet function, bleeding, and ischemic events in patients undergoing elective percutaneous coronary intervention. Thromb Haemost. https:\/\/doi.org\/10.1055\/s-0043-1772221","journal-title":"Thromb Haemost"},{"issue":"7","key":"2675_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","volume":"6","author":"K Mayer","year":"2021","unstructured":"Mayer K, Hein-Rothweiler R, Sch\u00fcpke S, Janisch M, Bernlochner I, Ndrepepa G, Sibbing D, Gori T, Borst O, Holdenrieder S, Kupka D, Petzold T, Bradaric C, Okrojek R, Leistner DM, Trippel TD, M\u00fcnzel T, Landmesser U, Pieske B, Zeiher AM, Gawaz MP, Hapfelmeier A, Laugwitz KL, Schunkert H, Kastrati A, Massberg S (2021) Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein VI, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial. JAMA Cardiol 6(7):753\u2013761. https:\/\/doi.org\/10.1001\/jamacardio.2021.0475","journal-title":"JAMA Cardiol"},{"issue":"9","key":"2675_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1055\/s-0039-1692423","volume":"119","author":"S Sch\u00fcpke","year":"2019","unstructured":"Sch\u00fcpke S, Hein-Rothweiler R, Mayer K, Janisch M, Sibbing D, Ndrepepa G, Hilz R, Laugwitz KL, Bernlochner I, Gschwendtner S, Kupka D, Gori T, Zeiher AM, Schunkert H, Massberg S, Kastrati A (2019) Revacept, a novel inhibitor of platelet adhesion, in patients undergoing elective PCI-design and rationale of the randomized ISAR-PLASTER trial. Thromb Haemost 119(9):1539\u20131545. https:\/\/doi.org\/10.1055\/s-0039-1692423","journal-title":"Thromb Haemost"},{"issue":"6","key":"2675_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrcardio.2009.76","volume":"6","author":"M Gawaz","year":"2009","unstructured":"Gawaz M, Geisler T (2009) Platelet activity: an obstacle for successful PCI. Nat Rev Cardiol 6(6):391\u2013392. https:\/\/doi.org\/10.1038\/nrcardio.2009.76","journal-title":"Nat Rev Cardiol"},{"issue":"20","key":"2675_CR17","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/eurheartj\/ehl275","volume":"27","author":"T Geisler","year":"2006","unstructured":"Geisler T, Langer H, Wydymus M, G\u00f6hring K, Z\u00fcrn C, Bigalke B, Stellos K, May AE, Gawaz M (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27(20):2420\u20132425. https:\/\/doi.org\/10.1093\/eurheartj\/ehl275","journal-title":"Eur Heart J"},{"issue":"1","key":"2675_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/eurheartj\/ehp402","volume":"31","author":"T Geisler","year":"2009","unstructured":"Geisler T, Z\u00fcrn C, Simonenko R, Rapin M, Kraibooj H, Kilias A, Bigalke B, Stellos K, Schwab M, May AE, Herdeg C, Gawaz M (2009) Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 31(1):59\u201366. https:\/\/doi.org\/10.1093\/eurheartj\/ehp402","journal-title":"Eur Heart J"},{"issue":"2","key":"2675_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","volume":"8","author":"D Sibbing","year":"2010","unstructured":"Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Sch\u00f6mig A, von Beckerath N, Kastrati A (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8(2):250\u2013256. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03709.x","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2675_CR20","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","volume":"18","author":"K Stark","year":"2021","unstructured":"Stark K, Massberg S (2021) Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 18(9):666\u2013682. https:\/\/doi.org\/10.1038\/s41569-021-00552-1","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"2675_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11239-010-0513-1","volume":"31","author":"CL Campbell","year":"2011","unstructured":"Campbell CL, Steinhubl SR, Hooper WC, Jozic J, Smyth SS, Bernstein D, De Staercke C, Syros G, Negus BH, Stuckey T, Stone GW, Mehran R, Dangas G (2011) Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. J Thromb Thrombolysis 31(2):139\u2013145. https:\/\/doi.org\/10.1007\/s11239-010-0513-1","journal-title":"J Thromb Thrombolysis"},{"issue":"2 Suppl","key":"2675_CR22","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/CCM.0b013e3181c98d21","volume":"38","author":"M Levi","year":"2010","unstructured":"Levi M, van der Poll T (2010) Inflammation and coagulation. Crit Care Med 38(2 Suppl):S26-34. https:\/\/doi.org\/10.1097\/CCM.0b013e3181c98d21","journal-title":"Crit Care Med"},{"issue":"18","key":"2675_CR23","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1161\/01.cir.102.18.2185","volume":"102","author":"KJ Haley","year":"2000","unstructured":"Haley KJ, Lilly CM, Yang JH, Feng Y, Kennedy SP, Turi TG, Thompson JF, Sukhova GH, Libby P, Lee RT (2000) Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102(18):2185\u20132189. https:\/\/doi.org\/10.1161\/01.cir.102.18.2185","journal-title":"Circulation"},{"issue":"1","key":"2675_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2005.07.002","volume":"186","author":"E Emanuele","year":"2006","unstructured":"Emanuele E, Falcone C, D\u2019Angelo A, Minoretti P, Buzzi MP, Bertona M, Geroldi D (2006) Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis 186(1):140\u2013145. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2005.07.002","journal-title":"Atherosclerosis"},{"issue":"7","key":"2675_CR25","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1161\/01.ATV.0000131654.90788.f5","volume":"24","author":"RB Kodali","year":"2004","unstructured":"Kodali RB, Kim WJH, Galaria II, Miller C, Schecter AD, Lira SA, Taubman MB (2004) CCL11 (eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler Thromb Vasc Biol 24(7):1211\u20131216. https:\/\/doi.org\/10.1161\/01.ATV.0000131654.90788.f5","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2675_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1365-2362.2006.01624.x","volume":"36","author":"C Falcone","year":"2006","unstructured":"Falcone C, Minoretti P, D\u2019Angelo A, Buzzi MP, Coen E, Emanuele E, Aldeghi A, Olivieri V, Geroldi D (2006) Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease. Eur J Clin Invest 36(4):211\u2013217. https:\/\/doi.org\/10.1111\/j.1365-2362.2006.01624.x","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2675_CR27","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/s41467-022-29341-1","volume":"13","author":"AK Rohlfing","year":"2022","unstructured":"Rohlfing AK, Kolb K, Sigle M, Ziegler M, Bild A, M\u00fcnzer P, Sudmann J, Dicenta V, Harm T, Manke MC, Geue S, Kremser M, Chatterjee M, Liang C, von Eysmondt H, Dandekar T, Heinzmann D, G\u00fcnter M, von Ungern-Sternberg S, B\u00fcttcher M, Castor T, Mencl S, Langhauser F, Sies K, Ashour D, Beker MC, L\u00e4mmerhofer M, Autenrieth SE, Sch\u00e4ffer TE, Laufer S, Szklanna P, Maguire P, Heikenwalder M, M\u00fcller KAL, Hermann DM, Kilic E, Stumm R, Ramos G, Kleinschnitz C, Borst O, Langer HF, Rath D, Gawaz M (2022) ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury. Nat Commun 13(1):1823. https:\/\/doi.org\/10.1038\/s41467-022-29341-1","journal-title":"Nat Commun"},{"issue":"2","key":"2675_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/s-0037-1613694","volume":"44","author":"S Maiocchi","year":"2018","unstructured":"Maiocchi S, Alwis I, Wu MCL, Yuan Y, Jackson SP (2018) Thromboinflammatory functions of platelets in ischemia-reperfusion injury and its dysregulation in diabetes. Semin Thromb Hemost 44(2):102\u2013113. https:\/\/doi.org\/10.1055\/s-0037-1613694","journal-title":"Semin Thromb Hemost"},{"issue":"24","key":"2675_CR29","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"D Trenk","year":"2012","unstructured":"Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, Richardt G, Jakubowski JA, Neumann FJ (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 59(24):2159\u20132164. https:\/\/doi.org\/10.1016\/j.jacc.2012.02.026","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2675_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/cvr\/cvn120","volume":"79","author":"R Kleemann","year":"2008","unstructured":"Kleemann R, Zadelaar S, Kooistra T (2008) Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 79(3):360\u2013376. https:\/\/doi.org\/10.1093\/cvr\/cvn120","journal-title":"Cardiovasc Res"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02675-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02675-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02675-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T06:08:13Z","timestamp":1753164493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02675-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2675"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02675-8","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest related to this work. The initial study (Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept in Patients With Chronic Coronary Syndromes Undergoing Percutaneous Coronary Intervention) was funded by the German Center for Cardiovascular Research (DZHK), Deutsches Herzzentrum M\u00fcnchen, Federal Ministry of Education and Research (BMBF), and advanceCOR GmbH (the manufacturer of Revacept, patent PCT\/EP2018\/067952). Tobias Harm receives research funding from the German Cardiac Society (DGK) Clinical Scientist Program. G\u00f6tz M\u00fcnch and Meinrad Paul Gawaz are co-founders of advanceCOR GmbH. Kristin Adler is an employee of advanceCOR GmbH. No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}